{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:31:37Z","timestamp":1786984297035,"version":"build-2736575974"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ajconline.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.amjcard.2025.06.006","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T18:53:12Z","timestamp":1749235992000},"page":"5-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Clinical Outcomes of Intravenous Iron Therapy in Systolic Heart Failure Patients Receiving SGLT2 Inhibitors"],"prefix":"10.1016","volume":"254","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3538-7564","authenticated-orcid":false,"given":"Waleed","family":"Alruwaili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seher","family":"Berzingi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalitsiri","family":"Atti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amro","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sittinun","family":"Thangjui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harshith","family":"Thyagaturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7872-3757","authenticated-orcid":false,"given":"Sudarshan","family":"Balla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.amjcard.2025.06.006_bib0001","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jacc.2021.11.039","article-title":"Criteria for Iron Deficiency in Patients With Heart Failure","volume":"79","author":"Masini","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"13","key":"10.1016\/j.amjcard.2025.06.006_bib0002","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1056\/NEJMoa1214865","article-title":"Treatment of anemia with darbepoetin alfa in systolic heart failure","volume":"368","author":"Swedberg","year":"2013","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.amjcard.2025.06.006_bib0003","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1161\/CIRCULATIONAHA.122.060511","article-title":"Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF","volume":"146","author":"Docherty","year":"2022","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.amjcard.2025.06.006_bib0004","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.amjcard.2025.06.006_bib0005","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ejhf.823","article-title":"Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis","volume":"20","author":"Anker","year":"2018","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.amjcard.2025.06.006_bib0006","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail"},{"issue":"48","key":"10.1016\/j.amjcard.2025.06.006_bib0007","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"issue":"10354","key":"10.1016\/j.amjcard.2025.06.006_bib0008","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.amjcard.2025.06.006_bib0009","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2025.06.006_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.630820","article-title":"Effects of Sodium-Glucose Co-transporter 2 Inhibitors on Hemoglobin Levels: A Meta-analysis of Randomized Controlled Trials","volume":"12","author":"Qu","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.amjcard.2025.06.006_bib0011","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.amjcard.2025.06.006_bib0012","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.amjcard.2025.06.006_bib0013","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jchf.2022.10.004","article-title":"Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure","volume":"11","author":"Packer","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.amjcard.2025.06.006_bib0014","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.cardfail.2022.12.007","article-title":"Combining Iron Supplements With SGLT2 Inhibitor-Stimulated Erythropoiesis in Heart Failure: Should We Be Worried About Thromboembolic Events?","volume":"29","author":"Packer","year":"2023","journal-title":"J Card Fail"},{"issue":"2","key":"10.1016\/j.amjcard.2025.06.006_bib0015","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"4","key":"10.1016\/j.amjcard.2025.06.006_bib0016","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity Analysis in Observational Research: Introducing the E-Value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.amjcard.2025.06.006_bib0017","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"10369","key":"10.1016\/j.amjcard.2025.06.006_bib0018","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.amjcard.2025.06.006_bib0019","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jchf.2023.11.006","article-title":"Meta-Analysis and Metaregression of the Treatment Effect of Intravenous Iron in Iron-Deficient Heart Failure","volume":"12","author":"Martens","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.amjcard.2025.06.006_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1186\/s12872-024-03961-5","article-title":"Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021","volume":"24","author":"Gonzalez","year":"2024","journal-title":"BMC Cardiovasc Disord"},{"issue":"8 Pt 1","key":"10.1016\/j.amjcard.2025.06.006_bib0021","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.jchf.2023.03.024","article-title":"Utilization Rates of SGLT2 Inhibitors Among Patients With Type 2 Diabetes, Heart Failure, and Atherosclerotic Cardiovascular Disease: Insights From the Department of Veterans Affairs","volume":"11","author":"Hussain","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"10266","key":"10.1016\/j.amjcard.2025.06.006_bib0022","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.amjcard.2025.06.006_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.mayocp.2014.10.007","article-title":"The Safety of Intravenous Iron Preparations: Systematic Review and Meta-analysis","volume":"90","author":"Avni","year":"2015","journal-title":"Mayo Clinic Proceedings"},{"issue":"3","key":"10.1016\/j.amjcard.2025.06.006_bib0024","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s00277-007-0416-1","article-title":"Iron and thrombosis","volume":"87","author":"Franchini","year":"2008","journal-title":"Ann Hematol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925003625?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914925003625?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:33:01Z","timestamp":1760099581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914925003625"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":24,"alternative-id":["S0002914925003625"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.06.006","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Outcomes of Intravenous Iron Therapy in Systolic Heart Failure Patients Receiving SGLT2 Inhibitors","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjcard.2025.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}